Exploration of Serum Exosomal LncRNA TBILA and AGAP2-AS1 as Promising Biomarkers for Diagnosis of Non-Small Cell Lung Cancer.
AGAP2-AS1.
Biomarker
Exosomes
Long non-coding RNAs
Non-small cell lung cancer
TBILA
Journal
International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
08
2019
accepted:
12
11
2019
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Non-small cell lung cancer is the most common type of cancer with a poor prognosis, and development of an effective diagnostic method is urgently needed. Exosomal lncRNAs, a class of transcripts longer than 200 nucleotides packaged into exosomes, have been defined as an ideal diagnostic biomarker for cancer. However, little is known about the clinical utility of exosomal lncRNAs in NSCLC. Here, we aimed to identify exosomal lncRNAs as promising biomarkers for NSCLC diagnosis. First, serum exosomes from NSCLC patients were successfully isolated by a polymer precipitation kit and then identified by TEM, NTA and western blot analysis. A total of nine candidate lncRNAs were detected by qRT-PCR in a training set. The two exosomal lncRNA TBILA and AGAP2-AS1 were screened out for the higher levels in NSCLC patients than that of healthy controls in a validation set. And there was a significant positive correlation between these exosomal lncRNAs levels and tumor size, lymph node metastasis and TNM stage. Additionally, we validated that these exosomal lncRNAs were stable in serum. Next, we evaluated the diagnostic efficiency of exosomal lncRNAs in NSCLC patients by ROC curve analysis. The data showed that individual TBILA or AGAP2-AS1 exhibited better diagnostic efficiency in NSCLC patients with different tumor pathologic subtypes and early stage, whereas the combination of lncRNAs did not provide better results than individual lncRNAs. Notably, the combination of two exosomal lncRNAs and the serum tumor biomarker Cyfra21-1 widely used in clinical practices further improved the diagnostic accuracy for NSCLC patients. This study suggests that exosomal lncRNA TBILA and AGAP2-AS1 may be promising biomarkers for diagnosis of NSCLC.
Identifiants
pubmed: 32015683
doi: 10.7150/ijbs.39123
pii: ijbsv16p0471
pmc: PMC6990900
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Long Noncoding
0
long non-coding RNA AGAP2-AS1, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
471-482Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
J Clin Oncol. 2013 Mar 10;31(8):992-1001
pubmed: 23401443
Nat Rev Genet. 2009 Mar;10(3):155-9
pubmed: 19188922
Biosens Bioelectron. 2019 Oct 1;142:111523
pubmed: 31336224
J Cell Physiol. 2019 Nov;234(11):20721-20727
pubmed: 31032916
Cancer Lett. 2018 Sep 28;432:156-168
pubmed: 29908210
Nucleic Acids Res. 2018 Jan 4;46(D1):D106-D112
pubmed: 30053265
J Clin Invest. 2016 Apr 1;126(4):1208-15
pubmed: 27035812
Onco Targets Ther. 2018 Aug 30;11:5269-5278
pubmed: 30214232
FASEB J. 2019 Jan;33(1):1151-1166
pubmed: 30148675
Clin Chim Acta. 2019 Aug;495:331-337
pubmed: 31054913
Curr Opin Cell Biol. 2009 Aug;21(4):575-81
pubmed: 19442504
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Cancer. 2017 Jul 11;16(1):118
pubmed: 28697764
Nucleic Acids Res. 2018 Jun 20;46(11):5809-5821
pubmed: 29931370
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Adv Clin Chem. 2015;72:107-70
pubmed: 26471082
Oncogene. 2018 Nov;37(44):5811-5828
pubmed: 29970904
Pharmacol Ther. 2017 Jun;174:63-78
pubmed: 28202367
Mol Cancer Ther. 2016 May;15(5):1082-94
pubmed: 26908628
J Transl Med. 2018 Aug 14;16(1):228
pubmed: 30107841
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Genet Test Mol Biomarkers. 2019 Apr;23(4):235-240
pubmed: 30986097
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
J Cell Mol Med. 2019 Feb;23(2):1396-1405
pubmed: 30467945
Biochem Biophys Res Commun. 2017 Aug 19;490(2):406-414
pubmed: 28623135
Cancer Res. 2016 Apr 1;76(7):1770-80
pubmed: 26992424
J Extracell Vesicles. 2014 Mar 26;3:null
pubmed: 24683445
Oncogene. 2018 Jul;37(28):3822-3838
pubmed: 29643475
J Control Release. 2019 Aug 28;308:119-129
pubmed: 31325471
Hematol Oncol. 2018 Dec;36(5):786-791
pubmed: 30144133
Curr Opin Cell Biol. 2014 Aug;29:116-25
pubmed: 24959705
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Cell Death Dis. 2016 May 19;7:e2225
pubmed: 27195672
Cell Death Dis. 2017 Oct 5;8(10):e3092
pubmed: 28981099
Mol Cancer. 2018 Feb 27;17(1):68
pubmed: 29486794
FASEB J. 2018 Jul;32(7):3957-3967
pubmed: 29466052
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Oncol Lett. 2019 Feb;17(2):2356-2364
pubmed: 30719111
BMC Pulm Med. 2019 Feb 28;19(1):55
pubmed: 30819158
Lab Invest. 2018 Sep;98(9):1133-1142
pubmed: 29967342
N Engl J Med. 2018 Sep 06;379(10):958-966
pubmed: 30184457
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Oncogene. 2018 Nov;37(47):6166-6179
pubmed: 30002443
Mol Cancer. 2018 Apr 24;17(1):84
pubmed: 29690888
Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39
pubmed: 25115305